Novel classes of drugs, such as oral tyrosine kinase inhibitors (ibrutinib, idelalisib) and BCL-2 protein antagonists, which induce apoptosis in leukemic cells, have received approval for the treatment of CLL patients [5, 6]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.